Oppenheimer raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $19 from $17 and keeps a Perform rating on the shares. The firm sees the Delaware court’s verdict in favor of Acadia as consistent with its expectations for Nuplazid intellectual property protection while removing a perceived overhang on the shares. The court specifically concluded that Acadia demonstrated by preponderance of evidence that Aurobindo infringes patent claims, the analyst tells investors in a research note. Opco now anticipates investor focus to reset back to key dynamics following the Q1 update and ahead of research and development day on June 25.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ACAD:
Disclaimer & DisclosureReport an Issue
